Rigor Reviewed

Rigor-Reviewed Manuscript

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Name: Αlpha¹ Rigor Record — Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Item: Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Rating: 59
Author: Αlpha¹

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 3 high issues for “Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Implausibly large reported effectAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper's core strengths are its rigorous randomized, double-blind, placebo-controlled parent trial with blinded adjudication, thorough demographic/biological-variable reporting, detailed statistical methods with assumption checks and plausible arithmetic, and conclusions that are transparently hypothesis-generating. Its main weaknesses are incomplete data/code availability (no sequencing accessions, no custom code), an under-identified investigational product (no dose/formulation), and a missing named regulatory-compliance framework, plus a minor main-text/figure inconsistency (missing minus sign in an ARR CI).

Full-text assessment by two independently sampled reviewer runs of the same model, which converged on six of eight dimension statuses; the one status divergence (data code availability warn vs fail) was resolved by weighing the data-availability statement as adequate, and minor sub-criterion divergences (randomization method detail, exact p-value practice) are noted in the relevant dimensions. Statistical verification recomputed 12 reported tests/effects consistently (threshold-only and exact/permutation p-values out of scope); citation check found 0 retracted and 0 not-found among 30 references; reproducibility links 4/4 live.

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 12 tests: 12 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 6 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions5 pass · 2 warn · 1 fail

Prior work on SGLT2 inhibitors reducing HHF, the heritability of CMPs, and the prevalence/risk of P/LP variants is cited with specific cohorts (Spanish DCM cohort, UK Biobank). The rationale links the premise to the objective (testing dapagliflozin benefit in variant carriers) and the hypothesis follows. Limitations of the design are extensively addressed in the Discussion (small carrier number, post-hoc nature, absent imaging, generalizability).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific foundation is well established and the rationale follows clearly from prior evidence.

Evidence

direct quote[Main, first two paragraphs]

“Sodium–glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin have been shown to prevent hospitalization for HF (HHF) across the spectrum of left ventricular ejection fraction (LVEF)”